Oppenheimer Downgrades Marinus Pharma to Perform, Announces $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has downgraded Marinus Pharma (NASDAQ:MRNS) from Outperform to Perform and set a price target of $14.
August 11, 2023 | 8:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marinus Pharma has been downgraded by Oppenheimer from Outperform to Perform with a price target of $14.
The downgrade from Outperform to Perform by Oppenheimer indicates a less optimistic outlook for Marinus Pharma. This could potentially lead to a decrease in the stock's price in the short term. The price target of $14 provides a benchmark for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100